Intellia Therapeutics, Inc. (NTLA) fundamentals score
Intellia Therapeutics, Inc. is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. Its mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments.
In Vitro & In Vivo Diagnostic Substances · Healthcare · Listed on NASDAQ
Overall: 4.7 out of 10, Weak long-term fundamentals
- Growth: 3.5/10
- Profitability: 4.0/10
- Financial health: 6.5/10
- Earnings quality: 6.7/10
- Valuation: 3.7/10
Scores are calculated from Intellia Therapeutics, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10